Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA

We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic

See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from

arabic
(عربى)

chinese
(中文)

english
(British)

farsi
(فارسی)

french
(Français)

german
(deutsch)

hebrew
(עִברִית)

hindi
(हिन्दी)

italian
(italiano)

Japanese
(日本語)

korean
(한국어)

portuguese
(Português)

spanish
(español)

vietnamese
(Tiếng Việt)

Our Team

Grishma Acharya, Senior Manager, In Vivo Pharmacology — **Grishma Acharya**, Senior Manager, In Vivo Pharmacology

Jocelyn Agliam, Administrative Assistant — **Jocelyn Agliam**, Administrative Assistant

Suzan Alayian, Accountant — **Suzan Alayian**, Accountant

Maher Alayyoubi, Principal Scientist, Drug Substance — **Maher Alayyoubi**, Principal Scientist, Drug Substance

Ray Ahn , Senior Manager, Analytical Development — **Ray Ahn** , Senior Manager, Analytical Development

Claudia Averbuj , Associate Director, Chemistry — **Claudia Averbuj** , Associate Director, Chemistry

James Barlow, Director of the Board — **James Barlow**, Director of the BoardBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/06/james_lighter_bg_d.jpg?time=1656027987
James Barlow
, Director of the Board
James Barlow is a member of the Board of Directors of NAHS Holding, Inc., an Employee Stock Ownership Plan company, whose affiliates provide post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than 30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations, financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. from January 2002 to March 2015, he oversaw financial due diligence, integration and structuring for all significant asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed Corporation and more than $4.5 billion in other transactions. He ensured consistent application of corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities. Prior to joining Allergan, Mr. Barlow served as Chief Financial Officer of Wynn Oil Company, a division of Parker Hannifin Corporation, during 2001, Treasurer and Controller of Wynn’s International, Inc. from 1990 to 2000 and Vice President and Controller of Ford Equipment Leasing Company from 1986 to 1990. From 1983 to 1985 Mr. Barlow worked for the accounting firm Deloitte Haskins and Sells. Mr. Barlow received a Bachelor of Science degree in Accounting, graduating magna cum laude, from Brigham Young University and a Master of Accountancy, graduating with honors - high distinction, from Brigham Young University. He is a certified public accountant (inactive).

Dina Berdieva, Vice President, Clinical Operations — **Dina Berdieva**, Vice President, Clinical OperationsBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/07/Dina-Berdivea-Vice-President-Clinical-Operations_317x317.png?time=1656027987
Dina Berdieva
, Vice President, Clinical Operations
Prior to joining Arcturus Therapeutics, Dina was one of the founding members of the Gates Medical Research Institute, serving as the Head of Project Management & Clinical Operations. Dina has 20 years of industry experience which spans small biotechnology, global pharmaceutical, and contract research organizations. Much of her career has been focused on the development of vaccines and treatments for infectious diseases. Dina holds a Bachelor of Arts degree from Clark University and a Master of Public Health degree from Boston University with a dual concentration in International Health Epidemiology and Biostatistics.

Stefen Boehme , Director, Head of Drug Discovery — **Stefen Boehme** , Director, Head of Drug Discovery

Babette de Boer , Principal Scientist, Toxicology — **Babette de Boer** , Principal Scientist, Toxicology

Natasha Bowman, Senior Vice President, Head of Human Resources — **Natasha Bowman**, Senior Vice President, Head of Human ResourcesBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2019/12/Natasha-Bowman-Vice-President-Head-of-Human-Resources-e1575574139326.jpg?time=1656027987
Natasha Bowman
, Senior Vice President, Head of Human Resources
Natasha O. Bowman, has more than 25 years of in the field of Human Resources with robust industry and leadership experience in the pharmaceutical, medical device, manufacturing and public sectors. Ms. Bowman most recently was the Senior Vice President of Human Resources at Synthetic Genomics for over 7 years where she served as a strategic adviser providing guidance on all HR related matters to the CEO, Board of Directors, and other members of the executive team. She previously held positions in start-up, mid-size, and Fortune 500 companies including Althea Technologies, ACADIA Pharmaceuticals and Pfizer Inc. where she played a key role in the start-up, growth, and mergers & acquisitions of those organizations. Ms. Bowman received a B.S in Business Management from San Diego State University. She was named as one of San Diego’s 500 Most Influential Business Leaders by the San Diego Business Journal in 2018, 2019, and 2020. She is on the Board of Directors for the non-profit organizations San Diego Girl Scouts, San Diego HR Forum, Lakeside River Park Conservancy, and Friends of Music.

Juthamart Brady, Research Associate, Drug Discovery — **Juthamart Brady**, Research Associate, Drug Discovery

Gabbi Caporusso , Clinical Development Associate — **Gabbi Caporusso** , Clinical Development Associate

Lena Ceballos, Manager, Corporate Communications & Marketing — **Lena Ceballos**, Manager, Corporate Communications & Marketing

Pad Chivukula, CSO, COO — **Pad Chivukula**, CSO, COOBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2022/04/Pad-Chivukula-April-21-2022-BW.jpg?time=1656027987
Pad Chivukula
, CSO, COO
Pad Chivukula, Ph.D., is the Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.

Jenny (Park) Choi , Associate Director, RNA Process Development — **Jenny (Park) Choi** , Associate Director, RNA Process Development

Brenda Clemente, Associate Director, Head of Formulation and Process Development — **Brenda Clemente**, Associate Director, Head of Formulation and Process Development

Diana Correa, Research Associate II, Analytical Development — **Diana Correa**, Research Associate II, Analytical Development

Connie Crowley , Executive Director, Senior Clinical Scientist — **Connie Crowley** , Executive Director, Senior Clinical Scientist

Alex Daily, Purchasing Manager — **Alex Daily**, Purchasing Manager

ThanhChau Dam, Senior Research Associate II, In Vivo Pharmacology — **ThanhChau Dam**, Senior Research Associate II, In Vivo Pharmacology

Michael Davis , Research Associate I, Formulation Development — **Michael Davis** , Research Associate I, Formulation Development

Michael Delbuono, Senior Research Associate I, Analytical Development — **Michael Delbuono**, Senior Research Associate I, Analytical Development

Yisong Deng, Scientist II, Analytical Development — **Yisong Deng**, Scientist II, Analytical Development

Nadja El-Mecharrafie, Senior Research Associate I, Frontier Science — **Nadja El-Mecharrafie**, Senior Research Associate I, Frontier Science

Michael Endow , Research Associate I, Drug Substance — **Michael Endow** , Research Associate I, Drug Substance

Peter Farrell, Chairman of the Board — **Peter Farrell**, Chairman of the BoardBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/10/portrait-bw3-Peter.jpg?time=1656027987
Peter Farrell
, Chairman of the Board
Dr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.

Adam Finochio, Research Associate I, Formulation Development — **Adam Finochio**, Research Associate I, Formulation Development

Cindy Fisher , Executive Director, Regulatory Affairs — **Cindy Fisher** , Executive Director, Regulatory Affairs

Daniel Garcia , Scientist I, Translational Biology — **Daniel Garcia** , Scientist I, Translational Biology

David Geller, Vice President, Clinical Development for Pulmonary and Rare Diseases — **David Geller**, Vice President, Clinical Development for Pulmonary and Rare DiseasesBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/08/David-Geller-Vice-President-Clinical-Development-for-Pulmonary-and-Rare-Diseases_317x317.jpg?time=1656027987
David Geller
, Vice President, Clinical Development for Pulmonary and Rare Diseases
David Geller is a pediatric pulmonologist with more than 30 years of clinical research experience in academic and industry settings. Prior to joining Arcturus Therapeutics, David spent 6 years at AbbVie where he led a cross-functional Clinical Strategy Team and Phase I-II studies for development of a combination CFTR-modulator therapy involving three novel compounds. Prior to that he conducted monoclonal antibody trials in cystic fibrosis (CF) and asthma at KaloBios. In academia David was Associate Clinical Professor at Florida State University School of Medicine and the University of Central Florida School of Medicine. David was responsible for the conduct of Phase I - IV trials in CF, asthma, and other respiratory disorders for numerous inhaled therapies, CFTR modulators, and biologics. He founded an academic aerosol research lab to study and improve drug-delivery efficiency to lungs and assist pharmaceutical/biotech sponsors to optimize delivery of their therapies with the appropriate delivery devices, and ultimately reduce time burden for patients. While in academia David also consulted for numerous pharma, biotech, and device companies on issues including aerosol delivery, protocol design, enrollment strategies, and messaging for marketing and education. David is dedicated to making a positive impact on the health of children and adults with cystic fibrosis (CF) and other rare, life-shortening diseases, and he has strong ties with the Cystic Fibrosis community including global CF Foundations and Societies, thought leaders and clinicians.

Kyra Gillard, Research Associate II, Translational Biology — **Kyra Gillard**, Research Associate II, Translational Biology

Nicole Gillies , Executive Assistant — **Nicole Gillies** , Executive Assistant

Arjan Hada , Scientist II, Formulation — **Arjan Hada** , Scientist II, Formulation

Abraham Gomez, Senior Research Associate, Translational Biology — **Abraham Gomez**, Senior Research Associate, Translational Biology

Jose Gonzales, Senior Research Associate II & Vivarium Supervisor — **Jose Gonzales**, Senior Research Associate II & Vivarium Supervisor

Jennifer Goodfellow, Executive Director, Strategic Sourcing Head — **Jennifer Goodfellow**, Executive Director, Strategic Sourcing Head

Yurong Guo, Director, Analytical Development — **Yurong Guo**, Director, Analytical Development

Kyle Gutsadt, Senior Analyst, Investor Relations & Public Relations — **Kyle Gutsadt**, Senior Analyst, Investor Relations & Public Relations

Paula Hartman, Project Manager — **Paula Hartman**, Project Manager

JP Headley, Senior Director of Accounting, Internal Audit, Facilities and Finance — **JP Headley**, Senior Director of Accounting, Internal Audit, Facilities and Finance

Steve Hughes, Strategic Clinical Advisor — **Steve Hughes**, Strategic Clinical AdvisorBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/08/Steve-Hughes-Chief-Development-Officer_Resize.jpg?time=1656027987
Steve Hughes
, Strategic Clinical Advisor
Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at leading biopharma companies. He has been involved in more than 50 clinical trials with more than 25 drugs across multiple therapeutic areas including cardiovascular, metabolic, neurology, oncology, infectious diseases, rheumatology, ophthalmology and several rare diseases, in the U.S. and globally. Dr. Hughes has also played a key role in the submission of multiple NDA/MAA applications. Most recently he served as the Chief Medical Officer of Organovo where he led the non-clinical and clinical development teams developing bioprinted tissues for treatment of hepatic and renal diseases. Prior to that he was Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of multiple drugs across several therapeutic areas. He has also held positions at Biogen Idec, CSL Behring and Sanofi. Dr. Hughes is Board Certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA from Imperial College Business School.

Michael Hodges, R&D & Medical Consultant — **Michael Hodges**, R&D & Medical ConsultantBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/10/Mike-Hodges-BW-22Sep2021_317x317.jpg?time=1656027987
Michael Hodges
, R&D & Medical Consultant
Michael R. Hodges, M.D., BSc. is a highly experienced and successful pharmaceutical industry veteran. He has worked on eight drug development programs in big PHARMA as the team leader/team member that have led to global regulatory approvals. Within biotech he has been part of teams that have raised Series B and C rounds of financing (~$150MM), one F-1 submission for IPO, one reverse merger and two successful M&As. He has deep disease-specific and RNA therapeutics technical expertise. He is currently supporting a number of Biotechnology companies in the role of drug development consultant, scientific advisor and/or board director. He is a member of the science advisory boards of Arcturus Therapeutics, Exicure Therapeutics and eFFECTOR Therapeutics and a scientific advisor for Adjuvant Capital. Michael was previously the Chief Medical Officer (CMO) of Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. The company was acquired by Pfizer, Inc. Prior to Amplyx he was the CMO for Santaris A/S, developing drug treatments for chronic viral diseases, cancer, metabolic/lipid and eye diseases. The company was acquired by Hoffman-La Roche, AG. Michael started his career in pharmaceutical medicines with Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Under his leadership two antifungal drugs where approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin). Michael was a Non-Executive Director of F2G Ltd., an infectious disease biotechnology company from 2010-2014. He earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.

Dr. Ed Holmes, Director of the Board — **Dr. Ed Holmes**, Director of the BoardBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2019/09/ed_holmes.jpg?time=1656027987
Dr. Ed Holmes
, Director of the Board
Dr. Holmes is currently a Distinguished Professor of Medicine at the University of California, Vice Chancellor/Dean of Health Sciences Emeritus at the University of California, San Diego, and CEO/President of the Sanford Consortium for Regenerative Medicine. He became the Executive Deputy Chairman of the Biomedical Research Council and the Executive Chairman of the National Medical Research Council in Singapore in October 2006; he is currently a Senior Fellow in A*STAR and Advisor to the National Research Council of Singapore. He holds an appointment as the Lien Ying Chow Professor of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. For his contributions to the Singapore government, Dr. Holmes was made an Honorary Citizen in 2011, and he was awarded the President’s Science and Technology Medal in 2017. Dr. Holmes also served on the Council of Advisors for the National Institute for Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health. He served as Chair of the Research Advisory Board of GlaxoSmithKline, the SAB of Ajinomoto and Board of Directors of Tularik, Inc. He also served on the Grand Challenges Explorations Innovation Review Panel for the Gates Foundation. He has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, Fellow of the American Association for the Advancement of Science, and a member of the United States National Academy of Medicine.

Hyojung Hong, Research Associate II-Technology Innovation and Development, Platform Formulation Development — **Hyojung Hong**, Research Associate II-Technology Innovation and Development, Platform Formulation Development

Hannah Huynh, Laboratory Coordinator — **Hannah Huynh**, Laboratory Coordinator

Hongfan Jin , Director, Bioanalytical — **Hongfan Jin** , Director, Bioanalytical

Michelle Kim, Research Associate II, Analytical Development — **Michelle Kim**, Research Associate II, Analytical Development

Mukunda Krishna, Associate Director, External Mfg, Technical Ops & Supply Chain — **Mukunda Krishna**, Associate Director, External Mfg, Technical Ops & Supply Chain

Kristen Kuakini, Senior Research associate I, Technical Ops & Supply Chain — **Kristen Kuakini**, Senior Research associate I, Technical Ops & Supply Chain

Greg Kubczak, Senior Director Manufacturing & CMC Supply Operations, Technical Ops & Supply Chain — **Greg Kubczak**, Senior Director Manufacturing & CMC Supply Operations, Technical Ops & Supply Chain

KC Kummerfeld, SVP Finance and Corporate Controller — **KC Kummerfeld**, SVP Finance and Corporate ControllerBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/10/portrait-bw3-KC-Kummerfeld.jpg?time=1656027987
KC Kummerfeld
, SVP Finance and Corporate Controller
K.C. Kummerfeld, CPA has over 20 years of financial executive experience working in fast paced companies within the Biotechnology and Technology industries. Prior to Arcturus, Mr. Kummerfeld worked in various Silicon Valley Technology Companies including Openwave Systems, Inc. where he held the role of Corporate Controller and helped establish the key accounting and finance controls necessary to grow the public company to over $400 million annual revenues and over 2,500 employees. Mr. Kummerfeld also worked for the accounting firm of KPMG after graduating from San Diego State University.

Lance Kurata, Chief Legal Officer — **Lance Kurata**, Chief Legal OfficerBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/08/Lance-Kurata-Chief-Legal-Officer_Resize.jpg.png?time=1656027987
Lance Kurata
, Chief Legal Officer
Lance Kurata has served as the Chief Legal Officer of Arcturus Therapeutics since August 2020. Prior to Arcturus, from 2006 to 2020, Mr. Kurata was a partner at Mintz Levin and Chair of the West Coast Technology Transactions Practice. From 2002 to 2006, he was a partner at Fish & Richardson, where he was a member of the corporate group and nationwide head of the technology transactions practice. From 1996 until 2002, Mr. Kurata practiced corporate law at Brobeck Phleger & Harrison, specializing in strategic collaborations, public and private financings, mergers and acquisitions and corporate governance. Mr. Kurata is licensed to practice law in the State of California. He received his Juris Doctor (JD) degree from Stanford Law School and was an editor of Stanford Law Review.

Annalee Ledesma, Associate Director, Program Management — **Annalee Ledesma**, Associate Director, Program Management

Angel Leu, Senior Research Associate II, Frontier Science — **Angel Leu**, Senior Research Associate II, Frontier Science

Pattraranee (Patty) Limphong, Director, Bioanalytical — **Pattraranee (Patty) Limphong**, Director, Bioanalytical

Kelly Lindert, Chief Development Officer, Vaccines — **Kelly Lindert**, Chief Development Officer, VaccinesBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/08/Kelly-Lindert-Senior-Vice-President-Head-of-Vaccine-Clinical-Development_317x317.jpg?time=1656027987
Kelly Lindert
, Chief Development Officer, Vaccines
Kelly Lindert is the Chief Development Officer, Vaccines. She has 20 years of experience in pharma and biotech industries and spent nearly ten years working on vaccines, including pandemic vaccines, at Acambis and Novartis. At Novartis she rose to serve as Head of Development and led the team for the approval of Fluad® and the first quadrivalent cell-based influenza vaccine in the US. More recently she worked at Moderna Therapeutics. She received her medical degree at the University of Chicago and trained in Urology at Stanford.

Rob Lopez, Facilities & Logistics Specialist — **Rob Lopez**, Facilities & Logistics Specialist

Tim Luger, Senior Research Associate I, Drug Substance — **Tim Luger**, Senior Research Associate I, Drug Substance

Brian Luk , Senior Scientist, Formulation Development — **Brian Luk** , Senior Scientist, Formulation Development

Quang Ly , Process Engineer II, Drug Product — **Quang Ly** , Process Engineer II, Drug Product

Dr. Jing L. Marantz, M.D., Ph.D, MBA, Director of the Board — **Dr. Jing L. Marantz, M.D., Ph.D, MBA**, Director of the BoardBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/12/Jing-Marantz-Dec-2021-BW-317x317-1.jpg?time=1656027987
Dr. Jing L. Marantz, M.D., Ph.D, MBA
, Director of the Board
Jing L. Marantz, M.D., Ph.D, MBA has over 20 years of experience in the biopharmaceutical industry spanning development, medical affairs, business development, and commercial strategy in multiple specialties and rare diseases. She is currently Senior Vice President, Head of Medical Affairs at Acceleron Pharma, Inc. Prior to Acceleron, Dr. Marantz served as Senior Vice President, Head of Medical Affairs with Alnylam Pharmaceuticals, Inc. where she built a medical organization into a global footprint across 19 countries and led two successful global product launches (ONPATTRO® and GIVLAARI®). Before Alnylam, she was Vice President, Global and U.S. Medical Affairs and interim Head of Latin America Medical Affairs with Alexion Pharmaceuticals, Inc. where she was responsible for 3 marketed rare disease products (SOLIRIS®, STRENSIQ®, and KANUMA®). Dr. Marantz previously held leadership positions at Biogen, Inc., ARIAD Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc. across development, medical affairs, and business development. She currently serves on the Board of Krystal Biotech, Inc. (NASDAQ: KRYS) where she chairs the Commercial Advisory Committee. Dr. Marantz was previously a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. She holds an MD from Tongji Medical College, a PhD in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California, Berkeley.

Dr. Magda Marquet, Director of the Board — **Dr. Magda Marquet**, Director of the BoardBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/05/Magda-Marquet.png?time=1656027987
Dr. Magda Marquet
, Director of the Board
Dr. Marquet is the co-Founder of ALMA Life Sciences, LLC, an early stage investment firm focusing on the creation and growth of innovative healthcare companies with an overall focus on prevention. She is also the co-Founder of AltheaDx, a commercial stage precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression. Dr. Marquet co-founded Althea Technologies in 1998 and led the company to the successful acquisition by Ajinomoto, a global Japanese company, leader in amino acid technology. During her tenure at Althea Technologies, Dr. Marquet had full P&L responsibility and built an organization with R&D and international commercial capabilities. Prior to starting Althea Technologies, Dr. Marquet held several positions in product development and pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals. She currently serves on the following Boards: Pfenex (PFNX) where she is a member of the Governance and Nomination Committee and Arcturus Therapeutics (ARCT) where is the Chairman of the Compensation Committee and a member of the Audit Committee. She also serves on the Board on several private companies such as Senté. As a former founder and CEO, Dr Marquet provides the Board with operational, fund raising expertise including venture, private equity and venture debt. She also brings expertise in M&A, global commercial development and regulatory strategies. She has a passion for building a winning culture of innovation and strategic growth. She holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous prestigious awards throughout her career including the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.

Alana Montoya, Senior Research Associate II, Drug Substance — **Alana Montoya**, Senior Research Associate II, Drug Substance

Rajesh Mukthavaram, Senior Manager, Formulation Development — **Rajesh Mukthavaram**, Senior Manager, Formulation Development

Kat Murphy, Senior Director, Clinical Operations — **Kat Murphy**, Senior Director, Clinical Operations

Andy Ngo, Research Associate II, RNA Production — **Andy Ngo**, Research Associate II, RNA Production

Jimmy Nguyen , Research Associate II, Technology Innovation and Development, Pharmaceutics Team — **Jimmy Nguyen** , Research Associate II, Technology Innovation and Development, Pharmaceutics Team

Raju Nilkanthache , Associate Director, Stability — **Raju Nilkanthache** , Associate Director, Stability

Maria Nunez , Associate Corporate Counsel — **Maria Nunez** , Associate Corporate Counsel

Cristine Ohlson, Contracts Administrator/Paralegal — **Cristine Ohlson**, Contracts Administrator/Paralegal

Ariel Olesco , Research Associate I, Technology Innovation and Development, Platform Formulation Development — **Ariel Olesco** , Research Associate I, Technology Innovation and Development, Platform Formulation Development

Mario Ornelas, Senior Manager, Quality — **Mario Ornelas**, Senior Manager, Quality

Jinho Park, Scientist II, Technology Innovation and Development, Pharmaceutics Team — **Jinho Park**, Scientist II, Technology Innovation and Development, Pharmaceutics Team

Suezanne Parker, Senior Vice President, Translational Biology — **Suezanne Parker**, Senior Vice President, Translational BiologyBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/10/portrait-bw3-suezanne-parker.jpg?time=1656027987
Suezanne Parker
, Senior Vice President, Translational Biology
Suezanne Parker has 25+ years of pharmaceutical industry experience in preclinical drug development from research/discovery through global marketing approvals with several paradigms (gene therapy, small molecules, biologics) in multiple therapeutic areas (Vaccines, Infectious Disease, Neurology, Immunology, Oncology, Ophthalmology, Rare Disease). During her career she has lead Discovery Research, Pharmacology, Toxicology/Pathology, Toxicological Risk Assessment, PK/ADME, Bioanalytical, and Nonclinical Regulatory Submissions Writing Departments. She joined Arcturus Therapeutics as the VP of Translational Biology in August 2018 where she is responsible for the development of Arcturus’s novel RNA medicine platforms. Prior to Arcturus, she was the Senior Director of Toxicology at Shire where her team supported the nonclinical efforts for the marketing applications for Xiidra®, Vyvanse®, and Takhzyro®, for Dry Eye Disease, Binge Eating Disorder, and the first mAb approved for hereditary angioedema, respectively. She also provided nonclinical guidance for Shire’s first Gene Therapy (AAV) programs. Prior to joining Shire, Suezanne was at Biogen Idec Pharmaceuticals where she was the site head for Nonclinical Development (Toxicology, Bioanalytical, PK/DM, and the Animal Facility) at the San Diego Campus. As the Director of Preclinical Safety at Biogen Idec, she supported marketed products for MS (Avonex®, Tysabri®, and Fampridine®) as well as developmental candidates from research/discovery through Late Stage Development. While at Biogen Idec, Suezanne was the preclinical safety lead for Rituxan®, Tecfidera®, Plegridy®, and Zinbryta® for multiple sclerosis. Suezanne started her career in Industry at Vical Inc. in San Diego CA where she was responsible for the management of Pharmacology, Preclinical Safety and the Animal Facility. At Vical, she led the preclinical efforts for some of the first in human trials for plasmid DNA therapy. Suezanne completed her postdoctoral studies at Scripps Clinic and Research Foundation studying the viral pathogenesis of CNS disease. She received her PhD in Biochemistry and Molecular Biology from the University of California, Santa Barbara.

Deep Patel, Senior Manager, MSAT — **Deep Patel**, Senior Manager, MSAT

Joseph E. Payne, President & CEO, Director of the Board — **Joseph E. Payne**, President & CEO, Director of the BoardBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2016/06/portrait-bw-joseph-payne.jpg?time=1656027987
Joseph E. Payne
, President & CEO, Director of the Board
Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.

Yihua Pei, Scientist II, Formulation Development — **Yihua Pei**, Scientist II, Formulation Development

Gregory Peters , Clinical Trial Supply Chain — **Gregory Peters** , Clinical Trial Supply Chain

Linda Quirino, Senior Research Associate, Translational Biology — **Linda Quirino**, Senior Research Associate, Translational Biology

Huda Rabi, Research Associate II, Formulation Development — **Huda Rabi**, Research Associate II, Formulation Development

Kumar Rajappan, Senior Principal Scientist, Chemistry — **Kumar Rajappan**, Senior Principal Scientist, Chemistry

Tyler Raymer, Senior Manager, Facilities — **Tyler Raymer**, Senior Manager, Facilities

Paloma Martinez Redondo, Senior Scientist, Translational Biology — **Paloma Martinez Redondo**, Senior Scientist, Translational Biology

Pamela Resch, Executive Director, Quality and Regulatory Affairs — **Pamela Resch**, Executive Director, Quality and Regulatory Affairs

Josie Rivera, Research Associate I — **Josie Rivera**, Research Associate I

Joseph Roberts, Assistant Controller — **Joseph Roberts**, Assistant Controller

Fred del Rosario, Senior Director, Information Technology — **Fred del Rosario**, Senior Director, Information Technology

Sunil Raju, VP, Head of Drug Safety and Pharmacovigilance — **Sunil Raju**, VP, Head of Drug Safety and PharmacovigilanceBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/07/Sunil-Raju-Vice-President-Drug-Safety.png?time=1656027987
Sunil Raju
, VP, Head of Drug Safety and Pharmacovigilance
Dr. Sunil Raju has over 12 years of industry experience across Drug Safety, Clinical Development and Medical Affairs in both large and small pharma. He is joining us from UroGen Pharma where he served as Vice President, Clinical Development and Pharmacovigilance. During his time there he was responsible for leading and building the Drug Safety department and played an instrumental role in the approval of their first product Jelmyto® for upper tract urothelial cancer (UTUC). He was also the Clinical Lead for their Phase 3 study of UGN-102 for non-muscle invasive bladder cancer (NMIBC). Previously, he spent 11 years at Pfizer where he worked across multiple roles initially in Medical Affairs (covering UK and Europe) and then transitioning to Drug Safety in the US where he held leadership roles in Worldwide Safety managing global teams across the US and China. In addition, he has experience of leading Drug Safety integrations of company acquisitions. Prior to joining industry, Sunil worked as a medical doctor in the UK specializing in Anesthesiology and Intensive Care having received his medical degree from Imperial College, London. He also holds a Bachelor of Sciences degree in Management from Imperial College.

Deepankar Roy , Senior Director, Investor Relations — **Deepankar Roy** , Senior Director, Investor Relations

Qian Ruan, VP, Technical Operations & Manufacturing — **Qian Ruan**, VP, Technical Operations & ManufacturingBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/03/Qian-Ruan-VP-Technical-Operations-Manufacturing.png?time=1656027987
Qian Ruan
, VP, Technical Operations & Manufacturing
Qian Ruan, Ph.D., is the Vice President of Technical Operations and Manufacturing of Arcturus Therapeutics. Dr. Ruan has extensive experience in bioprocess development from preclinical to licensure. Prior to Arcturus, Dr. Ruan worked at Emergent BioSolutions/PaxVax Inc. as Sr. Director of Process Development and Clinical Production. She has successfully built and led the team developed/manufactured/tech transferred oral delivery vectors and injectable virus-like particles for vaccines. She was the main contributor for multiple Investigational new drug (IND) and Biological Licensure Application (BLA) submissions. Her team supported AstraZeneca and Johnson & Johnson COVID-19 vaccine manufacturing at Emergent Bayview site to facilitate Emergency Use Authorization (EUA). Prior to Emergent BioSolutions/ PaxVax Inc, she worked for the Center of Cell and Gene Therapy at Baylor College of Medicine and developed early phase gene therapy drugs with adenovirus, herpes, and retrovirus platform technology. She published multiple articles and was the co-author of chapter “Purification of Adenovirus” in the book Adenoviral vectors for Gene Therapy. Qian holds a Ph.D. and a Bachelor's degree in Biochemical Engineering from South China University of Technology.

David Russo , Research Associate II, Analytical Development — **David Russo** , Research Associate II, Analytical Development

Cristiano Sacchetti, Senior Scientist, Bioanalytical — **Cristiano Sacchetti**, Senior Scientist, Bioanalytical

Hazel Santos, Accounts Payable Specialist — **Hazel Santos**, Accounts Payable Specialist

Andrew Sassine, Chief Financial Officer — **Andrew Sassine**, Chief Financial Officer

Noa Scott, Human Resources Manager — **Noa Scott**, Human Resources Manager

Kyle Scurlock, SEC Reporting Manager — **Kyle Scurlock**, SEC Reporting Manager

Rose Sekulovich, Vice President of Bioanalytical, Translational Biology — **Rose Sekulovich**, Vice President of Bioanalytical, Translational Biology

Henry Shafron, Research Associate II, Analytical Development — **Henry Shafron**, Research Associate II, Analytical Development

Anna Shishina , Scientist II, Analytical Development — **Anna Shishina** , Scientist II, Analytical Development

Donna Singh , Senior Document Specialist — **Donna Singh** , Senior Document Specialist

Ajit Simh, Senior Vice President, Head of Global Quality — **Ajit Simh**, Senior Vice President, Head of Global QualityBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/11/Ajit-Simh_BW.jpg?time=1656027987
Ajit Simh
, Senior Vice President, Head of Global Quality
Ajit Simh has been in the biopharmaceutical industry for a span of over three decades, across the globe. His experience includes manufacturing, operations, and quality assurance/compliance. He has successfully hosted United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA) pre-approval inspections resulting in product approvals. His background also includes recombinant proteins (from Eukaryotic and Prokaryotic cell lines), small molecules, vaccines, and Advanced Therapeutic Medicinal Products. Since 1994, Ajit has been actively involved in academia at the University of California, San Diego, and San Diego State University as an Instructor and Adjunct Professor. He teaches classes in Drug Development and Quality as well as Regulatory Compliance in the M.Sc. degree program in Regulatory Affairs. Ajit has a B.Sc. in Biology and Chemistry and a M.Sc. (Research) degree in Cell Biology from St. Louis University.

Matt Sharma, Senior Clinical Trial Manager — **Matt Sharma**, Senior Clinical Trial Manager

Kevin Skol, Senior Vice President, Business Development & Alliance Management — **Kevin Skol**, Senior Vice President, Business Development & Alliance ManagementBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2018/10/portrait-bw3-kevin-skol.jpg?time=1656027987
Kevin Skol
, Senior Vice President, Business Development & Alliance Management
Kevin Skol has nearly 20 years of experience in the pharmaceutical industry, primarily in corporate development, alliance management, strategy and licensing roles. He previously worked at RNA target-based companies Ionis Pharmaceuticals and Digital Gene Technologies and at specialty pharmaceutical companies Elan Corporation and Valeant Pharmaceuticals. At Ionis he led business development and licensing efforts that resulted in major pharmaceutical partnerships with Astra Zeneca, Roche, Janssen, Novartis and Biogen. The combined transaction value of collaborative agreements and partnerships which he led throughout his career is estimated at over $2 billion. Mr. Skol graduated with a B.A. from Yale University and has an MBA from Harvard Business School.

Claine Snow, Sr. IP & Transactions Counsel — **Claine Snow**, Sr. IP & Transactions Counsel

Benchawanna SoontornniyomkijI, Senior Research Associate I, Translational Biology — **Benchawanna SoontornniyomkijI**, Senior Research Associate I, Translational Biology

Tyler Spencer, Finance Manager — **Tyler Spencer**, Finance Manager

Brian Sullivan , Principal Scientist, Vaccines & Immunology — **Brian Sullivan** , Principal Scientist, Vaccines & Immunology

Sean Sullivan, Vice President, Head of Technology Innovation — **Sean Sullivan**, Vice President, Head of Technology Innovation

Kiyoshi Tachikawa, Executive Director, Frontier Science — **Kiyoshi Tachikawa**, Executive Director, Frontier Science

Viraj Talpade , Associate Director, IT Infrastructure & Security — **Viraj Talpade** , Associate Director, IT Infrastructure & Security

Wendy Taylor, Vice President, Operations — **Wendy Taylor**, Vice President, Operations

Phuong-Danh Tran, Research Associate II, Technology Innovation and Development, Pharmaceutics Team — **Phuong-Danh Tran**, Research Associate II, Technology Innovation and Development, Pharmaceutics Team

Ramon Diaz Trelles, Principal Scientist, Drug Discovery — **Ramon Diaz Trelles**, Principal Scientist, Drug Discovery

Dushyant Varshney, Executive Vice President & Chief Technology Officer — **Dushyant Varshney**, Executive Vice President & Chief Technology OfficerBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/01/Dushyant-Varshney_bw_resize.jpg?time=1656027987
Dushyant Varshney
, Executive Vice President & Chief Technology Officer
Dushyant B. Varshney, Ph.D., is the Executive Vice President & Chief Technology Officer. He is responsible for Global CMC, Technical Operations & Quality, including technology innovation, product development, manufacturing, technology transfer and commercialization of Drug Substance and Finished Drug Products. Dr. Varshney has over 25 years of experience at global bio-pharma organizations, leading the entire product life-cycle of diverse biotech modalities including mRNA therapeutics, gene & cell-based therapy, biologics and vaccines. He has made significant contributions towards 30+ launches, 75+ INDs, BLA, PAS submissions, and ensured supply of more than 7B+ doses, $20B+ revenues at companies including Gilead, Pfizer, Novartis and Sanofi. Before joining Arcturus, Dr. Varshney was the Global Head of Manufacturing, Science & Technology at Gilead-Kite, where he built a strong organization & rapid commercialization strategy for successful technology transfers, launch & patient access of Yescarta®, Tecartus®, viral vectors and clinical products. Prior to that, he served as the Vice President, Global Head of Technical Services, Operations & Supply at Jubilant, and as the Head of Manufacturing, Science & Technology at Pfizer, led America, Europe & Asia Pacific teams. At Novartis, contributed to commercial technology transfer, qualification, manufacturing of Flucelvax® (first US cell-based influenza vaccine) Trivalent & Quadrivalent, Pre-Pandemic Vaccine stockpiles (bird & swine-flu, H5N1, H3N2, H7N9), and pandemic response strategies. Dushyant received his Ph.D. in Chemistry from University of Iowa, M. Pharm from Institute of Chemical Technology, Mumbai, and B. Pharm from University of Pune in India. He is a Stephen Covey Leadership Coach, Master Black-Belt in Operational Excellence, made 120+ conference presentations, published 40+ articles, chapters and edited the book “Lyophilized Biologics & Vaccines” published by Springer.

Aishwarya Vasudevan , Research Associate II, Formulation Development — **Aishwarya Vasudevan** , Research Associate II, Formulation Development

Simone Ward, Senior IP Counsel, Life Science — **Simone Ward**, Senior IP Counsel, Life Science

Nancy Wilk , Benefits & Payroll Manager — **Nancy Wilk** , Benefits & Payroll Manager

Yuval Yarkoni , Senior Manager, Operational Technical Lead — **Yuval Yarkoni** , Senior Manager, Operational Technical Lead

Rodrigo Yelin, Director, Program Management — **Rodrigo Yelin**, Director, Program Management

Ye Zhang , Senior Vice President, Head of Regulatory Affairs — **Ye Zhang** , Senior Vice President, Head of Regulatory AffairsBio
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/12/Ye-Zhang-Vice-President-Head-of-Regulatory-Strategy-317x317-1.jpg?time=1656027987
Ye Zhang
, Senior Vice President, Head of Regulatory Affairs
Dr. Ye Zhang brings more than 17 years of regulatory and drug development experience in vaccines, biologics, and small molecules from both Merck and the FDA. Ye’s background is in both in clinical and CMC. She joins us from Merck where she was the Senior Director in Global Regulatory Affairs and Clinical Safety. In this role she was responsible for more than ten vaccines in development and life-cycle management. Ye has extensive experience in working with the FDA, MHRA, EMA and HC. Prior to joining Merck, she was at the FDA as a Drug Product Quality Reviewer, where she gained extensive regulatory experience in the CMC aspects of drug development and familiarity with the regulatory policies, guidance and procedures associated with IND, BLA/NDAs. Ye also worked at Merck before joining the FDA and joined Merck in 2006 as part of siRNA Therapeutic acquisition. During this time, she held team leader positions of increasing responsibility for biophysical and chemical characterization and GMP batch release to support preclinical and clinical development of siRNA drug candidates including lipid nanoparticles (LNPs) for oncology and infectious diseases. Ye holds a Ph.D. in Pharmaceutical Sciences from University of Colorado, an MS in Biochemistry and Molecular Biology from China-Japan Friendship Institute of Clinical Medical Sciences, and an M.D. from Medical School of Peking University. Ye is a member of the Biotechnology Innovation Organization (BIO) Vaccines Regulatory Affairs Committee (VacRAC) and Drug Information Association (DIA).

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.

News & Events

March 4, 2013

Arcturus Therapeutics Begins Operations in Janssen Labs

May 8, 2013

Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board

June 1, 2013

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

June 3, 2013

With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego

June 3, 2013

RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round

June 3, 2013

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

June 4, 2013

Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech

June 4, 2013

Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding

June 4, 2013

Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi

August 14, 2013

Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech

August 14, 2013

Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina

August 15, 2013

San Diego upstart acquires RNA tech from cash-strapped Marina Biotech

August 15, 2013

San Diego Life Sciences Roundup: Vical, Fate, Arcturus, and More

August 15, 2013

Arcturus Therapeutics Acquires Patent Portfolio from Marina Biotech

August 15, 2013

Marina Sells UNA Patent Estate to Arcturus as It Looks to Resume Operations

October 21, 2013

GenomeWeb Acturus Closes $5M Series A Round, Aims for Clinic in '15 with RNAi Drug

October 21, 2013

RNAi firm raises $5M to develop and deliver drugs that turn off disease-causing genes

September 22, 2021

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

October 12, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

October 20, 2021

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 21, 2021

Arcturus Therapeutics Announces Leadership Appointments

October 25, 2021

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

November 8, 2021

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

November 18, 2021

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 22, 2021

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

December 13, 2021

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

December 16, 2021

Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

January 24, 2022

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

January 25, 2022

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

February 8, 2022

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

February 16, 2022

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

February 28, 2022

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

March 25, 2022

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

April 20, 2022

Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

April 27, 2022

Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

May 5, 2022

Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

May 9, 2022

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress